Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Solu Therapeutics has raised $41.0M in total funding. The most recent round was Series A. The last funding was announced in April 2025.
Solu Therapeutics's investors include Eli Lilly, Longwood Fund, Sante Ventures, DCVC Bio, Pappas Capital.
Solu Therapeutics is headquartered in Boston, United States.
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Solu Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Solu Therapeutics — Funding & Investors." VCBacked, April 9, 2025, https://www.vcbacked.co/company/solu-therapeutics. Accessed October 25, 2026.
VCBacked. (2025). Solu Therapeutics — Funding & Investors. Retrieved October 25, 2026, from https://www.vcbacked.co/company/solu-therapeutics
{{cite web |title=Solu Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/solu-therapeutics |website=VCBacked |access-date=October 25, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated